DNA ploidy level and cell cycle distribution in ovarian cancer: relation to histopathological features of the tumor
other
OA: closed
public-domain-us
AI-generated summary
Flow cytometry revealed DNA aneuploidy and higher S-phase fraction in advanced, undifferentiated ovarian tumors, correlating with nuclear grade and indicating malignant potential.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We analyzed nuclear DNA content and S-phase fraction (SPF) from 157 paraffin-embedded ovarian tumors by flow cytometry and compared the results with the clinicopathological features of the tumors. DNA aneuploidy was more common and mean SPF was higher in advanced than in early-stage tumors (p less than 0.001). DNA aneuploidy was most often (75%) observed in undifferentiated tumors (World Health Organization classification) and most seldom (30%) in mucinous carcinomas. Mean SPF values ranged from 17.7% in undifferentiated carcinomas to 11.1% in mucinous carcinomas. DNA flow cytometric results correlated better with nuclear than with histological tumor grade. The proportion of DNA-aneuploid tumors increased from 30% in nuclear grade I to 93% in nuclear grade III, and mean SPF increased from 9.9 to 20.2% (p less than 0.001). DNA ploidy and SPF were independently associated with both stage and nuclear grade of the tumor, whereas the differences between the histopathological tumor types virtually disappeared when the groups were adjusted for nuclear grade. On the basis of these clinicopathological correlations, it appears that DNA ploidy and SPF reflect the malignant potential of ovarian tumors and thus complement the routine histopathological evaluation.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-06-19T06:14:56.452680+00:00
- pubmed
- last seen: 2026-05-13T22:09:25.758913+00:00
- unpaywall
- last seen: 2026-06-19T06:35:33.578913+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine